Vitrolife
VITR.ST Large CapHealthcare · Medical Devices
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Vitrolife en bref
Vitrolife (VITR.ST) is currently trading at 91,05 € with a market capitalization of 10,8 Md €. The 52-week range spans from 84,60 € to 153,50 €; the current price is 40.7% below the yearly high. Year-over-year revenue growth stands at -4.2%.
💰 Dividende
Vitrolife currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
4 analystes évaluent Vitrolife (VITR.ST) au consensus : None. L'objectif de cours moyen est de 162,75 €, soit un potentiel de +78.75% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 131,00 € à 215,00 €.
Vitrolife : la thèse d'investissement en détail
Vitrolife (VITR.ST) operates in the Healthcare — specifically Medical Devices — and is headquartered in Sweden. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
The combination of a 58.65% gross margin and 18.46% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.
Le scénario baissier
Revenue is contracting at -4.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 78.75% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 58.65% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 19.6)
- Free cash flow positif
- –CA en contraction (-4.2% sur un an)
- –Actuellement non rentable
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to above-average price swings.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Vitrolife?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
